Dosing & Uses
Anemia of Chronic Kidney Disease
Pending FDA approval for treatment of anemia of chronic kidney disease
Next:
Pharmacology
Mechanism of Action
Oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)
Inhibition of oxygen-sensing prolyl hydroxylase enzymes stabilizes hypoxia-inducible factors, which can lead to transcription of erythropoietin and other genes involved in the correction of anemia, similar to the physiological effects that occur in the human body at high altitude
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
